 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...8990919293949596979899...132133» |
- | Signifor (pasireotide) / Recordati
Trial completion, Trial completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Oct 18, 2018
P1, N=13, Completed, Sponsor: Emory University
Trial completion date: Mar 2019 --> Oct 2018 | Active, not recruiting --> Completed
- | simvastatin / Generic mfg.
Enrollment closed, Trial completion date: Safety of Simvastatin in LAM and TSC (clinicaltrials.gov) - Oct 17, 2018
P1/2, N=10, Active, not recruiting, Sponsor: University of Pennsylvania
Trial completion date: Mar 2019 --> Oct 2018 | Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jan 2018 --> May 2019
- | Trial completion, Trial completion date, Trial primary completion date: A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer (clinicaltrials.gov) - Oct 17, 2018
P1, N=21, Completed, Sponsor: Fox Chase Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Jan 2018 --> May 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Aug 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Oct 17, 2018
P2, N=13, Not yet recruiting, Sponsor: Yousef Zakharia
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Aug 2018 Trial completion date: Nov 2019 --> Apr 2021 | Initiation date: Oct 2018 --> Apr 2019 | Trial primary completion date: Nov 2019 --> Apr 2021
- | everolimus / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Everolimus for Children With Recurrent or Progressive Ependymoma (clinicaltrials.gov) - Oct 15, 2018
P2, N=10, Completed, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Nov 2019 --> Apr 2021 | Initiation date: Oct 2018 --> Apr 2019 | Trial primary completion date: Nov 2019 --> Apr 2021 Recruiting --> Completed | N=18 --> 10 | Trial completion date: Dec 2020 --> Jul 2018 | Trial primary completion date: Feb 2019 --> Jul 2018
- | Envarsus (LCP-Tacro) / Asahi Kasei
Trial primary completion date: Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients (clinicaltrials.gov) - Oct 11, 2018
P=N/A, N=40, Recruiting, Sponsor: Medical University of South Carolina
Recruiting --> Completed | N=18 --> 10 | Trial completion date: Dec 2020 --> Jul 2018 | Trial primary completion date: Feb 2019 --> Jul 2018 Trial primary completion date: Sep 2018 --> Jan 2019
- everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Oct 9, 2018
P2, N=4, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Sep 2018 --> Jan 2019 Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Enrollment change, Combination therapy, Metastases: TRINITI-1: Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (clinicaltrials.gov) - Oct 5, 2018
P1/2, N=107, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2019 --> Oct 2020 | Trial primary completion date: Sep 2018 --> Oct 2019 Recruiting --> Active, not recruiting | N=51 --> 107
- | itacitinib (INCB039110) / Incyte
New P1/2 trial, Combination therapy: Itacitinib + Everolimus in Hodgkin Lymphoma (clinicaltrials.gov) - Oct 4, 2018
P1/2, N=28, Not yet recruiting, Sponsor: University of Pennsylvania
- | everolimus / Generic mfg.
Enrollment change: Assessing DSA Formation, Diabetes, Viral Infections, Structural Kidney Changes With an Everolimus-based Regimen (ADVISE) (clinicaltrials.gov) - Oct 4, 2018
P4, N=40, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=51 --> 107 N=90 --> 40
- | fulvestrant / Generic mfg.
Trial completion date, Trial primary completion date, Real-world evidence, Real-world, Metastases: Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients (clinicaltrials.gov) - Oct 4, 2018
P=N/A, N=131, Active, not recruiting, Sponsor: Fudan University
N=90 --> 40 Trial completion date: Aug 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- || everolimus / Generic mfg.
Trial completion: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Oct 3, 2018
P2, N=33, Completed, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Aug 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Active, not recruiting --> Completed
- || xentuzumab (BI-836845) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 2, 2018
P1, N=164, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Nov 2016
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Oct 2, 2018
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Sep 2018 --> Nov 2016 Trial completion date: Sep 2021 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Jun 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Combination therapy, Metastases: KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Oct 1, 2018
P3, N=1050, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Sep 2021 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Jun 2019 N=707 --> 1050
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma (clinicaltrials.gov) - Oct 1, 2018
P2, N=306, Recruiting, Sponsor: Eisai Inc.
N=707 --> 1050 N=20 --> 306 | Trial completion date: Jun 2021 --> Sep 2019 | Trial primary completion date: Jan 2021 --> Sep 2019
- | Avastin (bevacizumab) / Roche
Trial termination, Metastases: Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy (clinicaltrials.gov) - Sep 26, 2018
P3, N=78, Terminated, Sponsor: National Cancer Institute (NCI)
N=20 --> 306 | Trial completion date: Jun 2021 --> Sep 2019 | Trial primary completion date: Jan 2021 --> Sep 2019 Active, not recruiting --> Terminated
- | everolimus / Generic mfg.
Journal: Erythema nodosum arising during everolimus therapy for tuberous sclerosis complex. (Pubmed Central) - Sep 22, 2018
Everolimus is generally well tolerated, but it is important for physicians to identify and manage associated cutaneous adverse effects. We report the first case of a child developing erythema nodosum while undergoing everolimus therapy.
- | everolimus / Generic mfg.
Trial primary completion date: NFC-RAD001: Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas (clinicaltrials.gov) - Sep 20, 2018
P2, N=23, Active, not recruiting, Sponsor: University of Alabama at Birmingham
We report the first case of a child developing erythema nodosum while undergoing everolimus therapy. Trial primary completion date: Jun 2018 --> Dec 2018
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, Kineret (anakinra) / SOBI
Enrollment change, Trial completion date, Combination therapy, Metastases: NCI-2018-01842: Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers (clinicaltrials.gov) - Sep 20, 2018
P1, N=147, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2018 --> Dec 2018 N=57 --> 147 | Trial completion date: Jun 2021 --> Jun 2020
- | everolimus / Generic mfg.
Journal: Kaposi sarcoma-associated herpesvirus latency locus renders B cells hyperresponsive to secondary infections. (Pubmed Central) - Sep 20, 2018
The development of neutralizing antibodies against ZIKV was augmented in BALB/c-latency mice. Hyperglobulinemia was dampened by everolimus, a derivative of rapamycin, suggesting a role for mTOR inhibitors in managing immune activation, which is hallmark of KSHV infection as well as HIV infection.
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Sep 19, 2018
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Hyperglobulinemia was dampened by everolimus, a derivative of rapamycin, suggesting a role for mTOR inhibitors in managing immune activation, which is hallmark of KSHV infection as well as HIV infection. Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Jul 2019 --> Dec 2019
- | Enrollment change: Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity (clinicaltrials.gov) - Sep 19, 2018
P=N/A, N=2, Terminated, Sponsor: Montefiore Medical Center
Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Jul 2019 --> Dec 2019 N=30 --> 2
- | letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Sep 18, 2018
P2, N=74, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=30 --> 2 Trial primary completion date: Jun 2017 --> Jan 2018
- | everolimus / Generic mfg.
Enrollment change, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Sep 18, 2018
P3, N=110, Active, not recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Trial primary completion date: Jun 2017 --> Jan 2018 N=253 --> 110
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TRINITI-1: Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (clinicaltrials.gov) - Sep 18, 2018
P1/2, N=51, Recruiting, Sponsor: Novartis Pharmaceuticals
N=253 --> 110 Trial completion date: May 2018 --> Jul 2020 | Trial primary completion date: May 2018 --> Oct 2018
- | everolimus / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: SAGE: Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (clinicaltrials.gov) - Sep 17, 2018
P2, N=20, Terminated, Sponsor: Fox Chase Cancer Center
Trial completion date: May 2018 --> Jul 2020 | Trial primary completion date: May 2018 --> Oct 2018 N=43 --> 20 | Trial completion date: Jul 2019 --> Aug 2018 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Aug 2018; Extreme toxicity, met toxicity stopping rules
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial primary completion date, Metastases: Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy (clinicaltrials.gov) - Sep 17, 2018
P3, N=78, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=43 --> 20 | Trial completion date: Jul 2019 --> Aug 2018 | Recruiting --> Terminated | Trial primary completion date: Jul 2019 --> Aug 2018; Extreme toxicity, met toxicity stopping rules N=700 --> 78 | Trial primary completion date: Jul 2018 --> Dec 2017
- | Signifor LAR (pasireotide long acting release) / Recordati
Trial primary completion date, Combination therapy, Metastases: Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs (clinicaltrials.gov) - Sep 14, 2018
P1, N=18, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=700 --> 78 | Trial primary completion date: Jul 2018 --> Dec 2017 Trial primary completion date: Dec 2018 --> May 2020
- | everolimus / Generic mfg., exemestane / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, Metastases: EVEREXES: Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Sep 13, 2018
P3, N=236, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2018 --> May 2020 Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy, Metastases: KEYNOTE-581: Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Sep 13, 2018
P3, N=707, Recruiting, Sponsor: Eisai Inc.
Trial completion date: Dec 2017 --> Sep 2018 | Trial primary completion date: Dec 2017 --> Sep 2018 Trial completion date: Jan 2020 --> Feb 2021 | Trial primary completion date: Oct 2019 --> Apr 2020
- || Xofigo (radium Ra-223 dichloride) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer (clinicaltrials.gov) - Sep 10, 2018
P2, N=283, Active, not recruiting, Sponsor: Bayer
Trial completion date: Jan 2020 --> Feb 2021 | Trial primary completion date: Oct 2019 --> Apr 2020 Trial completion date: Mar 2019 --> Jul 2019 | Trial primary completion date: Aug 2018 --> Jul 2019
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 10, 2018
P1, N=45, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Mar 2019 --> Jul 2019 | Trial primary completion date: Aug 2018 --> Jul 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- | everolimus / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: Effect of Vitamin D on Everolimus Trough Concentrations Among Heart Transplanted Patients (clinicaltrials.gov) - Sep 6, 2018
P=N/A, N=300, Enrolling by invitation, Sponsor: Sheba Medical Center
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Jun 2018 --> Nov 2018 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Oct 2018
- |||| xentuzumab (BI-836845) / Boehringer Ingelheim
New P2 trial, Combination therapy, Metastases: The XENERA (clinicaltrials.gov) - Sep 5, 2018
P2, N=90, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||| Kisqali (ribociclib) / Novartis
Enrollment open, Enrollment change, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Sep 5, 2018
P2, N=76, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jun 2018 --> Nov 2018 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Oct 2018 Active, not recruiting --> Recruiting | N=15 --> 76
- | Signifor LAR (pasireotide long acting release) / Recordati
Trial completion date, Trial primary completion date: 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (clinicaltrials.gov) - Sep 1, 2018
P2, N=120, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting | N=15 --> 76 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Dec 2015
- | cisplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Trial completion date, Metastases: Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Aug 31, 2018
P1/2, N=55, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Dec 2015 Trial completion date: Jul 2018 --> Aug 2017 | Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: MOST plus: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (clinicaltrials.gov) - Aug 31, 2018
P2, N=560, Recruiting, Sponsor: Centre Leon Berard
Trial completion date: Jul 2018 --> Aug 2017 | Active, not recruiting --> Completed Trial completion date: Nov 2019 --> Oct 2022 | Trial primary completion date: Jul 2018 --> Jan 2020
- | everolimus / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). (Pubmed Central) - Aug 31, 2018
Trial completion date: Nov 2019 --> Oct 2022 | Trial primary completion date: Jul 2018 --> Jan 2020 No abstract available
- | cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
New P1/2 trial: LITMMUS-UCSF: Liver Transplantation With Tregs at UCSF (clinicaltrials.gov) - Aug 31, 2018
P1/2, N=9, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | Farydak (panobinostat) / Secura Bio
Enrollment open, Combination therapy: A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas (clinicaltrials.gov) - Aug 27, 2018
P2, N=32, Recruiting, Sponsor: University of Michigan Cancer Center
No abstract available Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Trial initiation date: A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients (clinicaltrials.gov) - Aug 27, 2018
P=N/A, N=12, Not yet recruiting, Sponsor: Roberto Gedaly
Not yet recruiting --> Recruiting Initiation date: Apr 2018 --> Sep 2018
- | everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Trial completion date, Trial primary completion date, Post-transplantation: Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function (clinicaltrials.gov) - Aug 24, 2018
P3, N=390, Recruiting, Sponsor: Poitiers University Hospital
Initiation date: Apr 2018 --> Sep 2018 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Trial completion, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Aug 22, 2018
P2, N=317, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy (clinicaltrials.gov) - Aug 22, 2018
P1, N=19, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Active, not recruiting --> Completed Recruiting --> Completed | N=33 --> 19 | Trial primary completion date: Sep 2017 --> Jan 2017
- ||| cyclosporin A microemulsion / Generic mfg., everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Trial completion date, Trial primary completion date: Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (clinicaltrials.gov) - Aug 21, 2018
P3, N=90, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
Recruiting --> Completed | N=33 --> 19 | Trial primary completion date: Sep 2017 --> Jan 2017 Trial completion date: May 2017 --> Aug 2018 | Trial primary completion date: May 2017 --> Aug 2018
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial initiation date, Combination therapy: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Aug 21, 2018
P1/2, N=132, Recruiting, Sponsor: Eisai Inc.
Trial completion date: May 2017 --> Aug 2018 | Trial primary completion date: May 2017 --> Aug 2018 Trial completion date: Dec 2022 --> May 2022 | Initiation date: Aug 2017 --> Nov 2017
- || Enrollment closed, Trial completion date, Trial primary completion date, Metastases: SAFIR-TOR: Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor (clinicaltrials.gov) - Aug 16, 2018
P=N/A, N=150, Active, not recruiting, Sponsor: UNICANCER
Trial completion date: Dec 2022 --> May 2022 | Initiation date: Aug 2017 --> Nov 2017 Recruiting --> Active, not recruiting | Trial completion date: Jan 2021 --> Sep 2021 | Trial primary completion date: Jan 2018 --> Sep 2018
- | Farydak (panobinostat) / Secura Bio
New P2 trial, Combination therapy: A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas (clinicaltrials.gov) - Aug 15, 2018
P2, N=32, Not yet recruiting, Sponsor: University of Michigan Cancer Center